[Contraception using 3-monthly injections of Depo-Provera].

C. Revaz,H. Welti,A. Dettling

Abstract:The injectable contraceptive Depo-Provera is used by about 1 million women mostly in Europe. It consists of an injection of 150 mg of medroxyprogesterone acetate every 3 months; the drug suppresses ovulation modifies the endometrium and the consistency of cervical mucus. In a clinical study of 100 cases effectiveness proved to be excellent the Pearl index being between 0-0.77 comparable to that for oral contraceptives (OCs). Side effects are minimal and limited to nausea and headache; there can however be an increase in bodyweight. The major complications are irregular bleeding and spotting; metrorrhagia intervenes in 70% of cases and amenorrhea in 55-75% of cases. These inconvenients can be eliminated by administration of estrogen by anticipating the next injection of Depo-Provero or by administering an oral contraceptive during the first 3-6 cycles after the first injection. Reversibility after Depo-Provera is slower than with other methods; ovulation reappears spontaneously 6-12 months after the last injection. In difficult cases ovulation can be reestablished with ovulation inductors. Continuation rate is 60-75% of users after 1 year and 45-60% of users after 2 years a rate comparable to that for OCs. It has not been proven that Depo-Provera has carcinogenic effects on the cervical and breast tissues.